Comments – All Patients to Receive ASAb
• Continue for up to 12 h at the discretion of the physician.
• Double bolus is recommended to support PCI in STEMI as the recommended adult
dosage of eptifibatide in patients with normal renal function.
• Infusion should be continued for 12-18 h at the discretion of the physician.
• Increased dosing over previous recommendation.
• Continue for up to 18 h at the discretion of the physician.
• A lower-dose regimen for tirofiban is FDA approved and has been shown to be
effective when used to treat UA/NSTEMI patients who are started on medical
therapy and when there is a substantial delay to angiography/PCI (eg, 48 h):
▶▶ LD of 50 mcg/mL administered at an initial rate of 0.4 mcg/kg per min for 30 min
▶▶ MD of a continuous infusion of 0.1 mcg/kg per min. Continue the infusion
through angiography and for 12-24 h after angioplasty or atherectomy.
• Optimum LD requires clinical consideration.
• Dose for patients ≥75 y of age has not been established.
• There is a recommended duration of therapy for all post-PCI patients receiving a
BMS or DES.
• Caution should be exercised for use with a PPI.
• Period of withdrawal before surgery should be at least 5 d.
(For full explanations, see footnote.)
• There are no data for treatment with prasugrel before PCI.
• MD of 5 mg orally per d in special circumstances.
• Special dosing for patients <60 kg or ≥75 y of age.
• There is a recommended duration of therapy for all post-PCI patients receiving a
DES.
• Contraindicated for use in patients with prior history of TIA or stroke.
• Period of withdrawal before surgery should be at least 7 d.
(For full explanations, see footnote.)
(Continued on next page) 19
